Investigation of REcurrence Mechanisms to Adjuvant osimertINib in Radically Resected EGFR-mutated NSCLC Patients

Sponsor
Gruppo Oncologico Italiano di Ricerca Clinica
Study ID
NCT07363252
Status
Recruiting
Apply to this trial

Conditions

  • EGFR-mutated NSCLC

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Osimertinib — DRUG
    Characterization of the molecular mechanisms of recurrence to adjuvant osimertinib

Study Details

Retrospective-prospective observational multicentric study including radically resected EGFR-mutated NSCLC patients relapsed during or after adjuvant osimertinib, received according to clinical practice

Key Dates

Start date
Apr 14, 2026
Status verified
Jan 2026
Primary completion
Dec 31, 2028
Completion
Dec 31, 2028

Study Design

Enrollment
100 participants (estimated)

Primary Outcome Measure

The primary endpoint of the study is the frequency of new variant(s) detected by Next Generation Sequencing (NGS) Panel at the time of recurrence to adjuvant osimertinib in tissue and/or liquid biopsy [ Time Frame: 3 years ]

Central Contacts

Related Studies